Alcresta Therapeutics has announced new real-world data published in Nutrients showing that use of RELiZORB in children aged 1 to 5 years led to statistically significant improvements in both weight and body mass index (BMI) z-scores over a 12-month period. The data further reinforce RELiZORB’s utility in pediatric tube-fed patients with fat malabsorption, including those with cystic fibrosis and short bowel syndrome, and follow recent FDA clearance expanding the product’s use across all pediatric age groups.

What this data signals about the maturing clinical profile of RELiZORB in pediatrics

The new data mark a clinically relevant step for RELiZORB’s positioning beyond initial adult and adolescent indications. The retrospective study assessed real-world use among children initiating RELiZORB between ages 1 and 5, demonstrating consistent improvements in weight and BMI z-scores by 12 months, with gains emerging as early as three months. Importantly, these findings come without new safety signals, adding weight to the product’s expanding label and adoption prospects.

Unlike earlier trials that primarily involved children over five or adults, this dataset extends real-world validation into a much younger cohort, overlapping with critical growth phases often complicated by fat malabsorption. Pediatric patients with cystic fibrosis and short bowel syndrome frequently face challenges achieving adequate caloric intake despite tube feeding, making enzyme-mediated absorption a therapeutic focal point. For this age group, even modest gains in z-scores can signal meaningful clinical improvements in developmental trajectory, particularly when tracked longitudinally across 12 months.

RELiZORB functions by hydrolyzing fats in enteral formula via immobilized lipase prior to ingestion, mimicking pancreatic enzyme activity for those with pancreatic insufficiency. Alcresta’s proprietary iLipase enzyme platform has enabled the company to design RELiZORB for compatibility across both bolus and continuous feeding systems, supporting diverse inpatient and at-home care settings.

Why real-world evidence matters more in pediatric tube feeding than randomized trials alone

While randomized controlled trials (RCTs) remain the gold standard for regulatory approval, industry observers note that in enteral nutrition—especially for rare or complex pediatric indications—real-world data often drive actual clinical decision-making. This is particularly true when small populations, ethical constraints, and individualized care plans limit the generalizability of RCTs.

In this context, Alcresta’s ability to produce robust, retrospective data from real-world settings enhances RELiZORB’s credibility and practical relevance. Clinicians tracking nutritional interventions for pediatric patients often seek longitudinal, observational data to complement trial findings, especially when managing conditions like cystic fibrosis that demand multi-pronged interventions over years.

This publication builds on previous evaluations involving neonates and infants under one year of age, further supporting RELiZORB’s label expansion. In April 2025, RELiZORB became the first and only FDA-cleared enzyme cartridge indicated for all age groups, marking a significant regulatory milestone. The current dataset now reinforces that decision with longer-term, post-clearance growth data.

What this expands in the treatment paradigm for fat malabsorption disorders

The implications for clinical practice extend beyond weight metrics. In patients with cystic fibrosis, effective fat absorption directly correlates with pulmonary outcomes, energy availability, and immune function. For short bowel syndrome, where intestinal surface area is already compromised, pre-digestion of fats via an external device may mitigate the need for parenteral nutrition or hospital-based interventions.

By ensuring that dietary lipids are hydrolyzed before entering the gastrointestinal tract, RELiZORB may fill a therapeutic gap not adequately addressed by pancreatic enzyme replacement therapy (PERT) alone. Many clinicians are already familiar with the challenges of PERT in tube-fed populations, where dosing can be inconsistent and efficacy variable depending on timing and formula type. RELiZORB’s inline functionality, combined with its compatibility with both continuous and bolus feedings, positions it as a potential standard adjunct in pediatric enteral therapy.

Additionally, the broader device usability introduced in the next-generation RELiZORB rollout in May 2024, which includes enhanced formula compatibility and increased frequency of daily use, may help clinicians better tailor regimens to individual metabolic needs.

What could constrain further adoption despite strong efficacy signals

Despite its expanding clinical footprint, RELiZORB’s real-world uptake may still face challenges in payer coverage, caregiver training, and cost-effectiveness thresholds. Tube-fed patients, especially in the pediatric segment, are often managed through multidisciplinary teams that include dietitians, nurses, and case managers. Device adoption in this environment hinges on integration into existing workflows and the demonstration of not just efficacy, but overall value—including reduced hospitalizations, fewer complications, or better caregiver-reported outcomes.

Moreover, although this study strengthens RELiZORB’s growth claims, it does not fully address durability of response, head-to-head comparison with PERT alternatives, or quality-of-life measures for patients and families. Industry analysts suggest that future prospective studies including comparative cohorts or health economic evaluations may help solidify RELiZORB’s positioning in national guidelines and formularies.

Clinicians will also want to understand the impact of formula type, feeding schedule, and underlying diagnosis on RELiZORB’s efficacy. While the current study encompassed both cystic fibrosis and other malabsorptive conditions like short bowel syndrome, subgroup analyses would clarify which patients benefit most.

What industry observers will be watching next

The broader enzyme therapy and pediatric nutrition markets will likely view this dataset as a validation of Alcresta Therapeutics’ R&D investment in real-world evidence generation. Yet, questions remain around whether RELiZORB can scale commercially across hospital systems, home health agencies, and Medicaid-dependent populations.

Regulatory watchers may also track whether additional claims or indications will be submitted for FDA consideration based on accumulating post-marketing data. With other players in the enteral nutrition space investing in formulation innovation, the competitive dynamic could soon shift from enzyme efficacy alone to delivery modality, caregiver usability, and outcome-linked reimbursement.

From a pipeline perspective, Alcresta’s platform expansion into the neonatal intensive care unit (NICU) space, including prematurely born infants, is likely to become the next growth lever. Whether RELiZORB can demonstrate outcome improvements in even more fragile patient populations could be pivotal to long-term payer and institutional acceptance.

RELiZORB’s new real-world data reinforces its role as a viable fat absorption aid for pediatric tube-fed patients, particularly those aged 1 to 5 years with cystic fibrosis or other malabsorptive conditions. The statistically significant improvements in weight and BMI z-scores underscore clinical value during critical developmental periods. The study bolsters the rationale behind the product’s FDA label expansion and may support broader use, especially as evidence continues to accumulate in younger cohorts.

Still, scalability, payer coverage, and comparative efficacy remain key hurdles to widespread integration. Stakeholders across pediatric nutrition, gastroenterology, and rare disease therapy will closely watch Alcresta’s next steps, particularly in terms of adoption pathways, prospective trials, and regulatory strategy.

  Alcresta Therapeutics, cystic fibrosis, enzyme therapy, fat malabsorption, pediatric nutrition, RELiZORB, short bowel syndrome